Arlington, VA: Over the past two months, the Digital Therapeutics Alliance (DTA) has petitioned governmental bodies across the world to provide their citizens with access to clinically-validated digital therapeutic (DTx) products. DTA has communicated with governments in Australia, Finland, France, Germany, Saudi Arabia, Scotland, Spain, United Arab Emirates, United Kingdom, United States, and the European Union. Communications have been provided in the appropriate languages, including Arabic, English, French, German, and Spanish.
DTA advised governments on how DTx products should play a critical role both during and after the Covid-19 pandemic. Digital therapeutics benefit clinicians and patients by expanding access in the following ways:
DTA Executive Director Megan Coder notes, “patient utilisation of digital therapeutics has the ability to improve health outcomes following the Covid-19 outbreak, optimize concurrent therapies, and minimize co-morbidities. This may help reduce otherwise unnecessary hospitalisations, assist healthcare professionals in triaging critical patient needs, and reduce vulnerable populations’ potential coronavirus exposure.”
As part of this campaign, the Digital Therapeutics Alliance highlighted to policymakers ways that specific DTx products could impact individual and population-level needs. While product availability varies between countries, health conditions and disease states addressed by digital therapeutics include alcohol use disorder, anxiety, asthma, chronic pain, chronic obstructive pulmonary disease (COPD), depression, diabetes (type 1 and 2), insomnia, and other mental and behavioral health disorders.
“We are committed to expanding patient access to high quality digital therapeutics across the world,” shares Jessica Shull, DTA European Lead. “In many countries, the lack of governmental recognition and reimbursement of DTx products has become a major healthcare barrier. We are particularly encouraged however by efforts taking place in countries such as Germany, where the first national financing framework for digital products has been created.”
Digital therapeutics deliver therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of behavioral, mental, and physical diseases and disorders. These products differ from health and wellness apps, telehealth platforms, or tools solely designed for monitoring, diagnostic, and adherence purposes. DTx products comply with rigorous patient-centered core principles and best practices to ensure product integrity, user-centered designs, patient privacy through GDPR (in the EU), and validated clinical outcomes via randomized controlled trials (RCT) and real world evidence (RWE).
“Quality, access, and appropriate utilization are critical for all DTx products,” emphasized Coder. “We support quality standards to ensure that patients and clinicians can be assured they are accessing a trustworthy treatment that has undergone rigorous clinical research. Building on the ease of product scalability and access through patient-owned devices, DTx products can more easily reach high-risk, rural, and underserved communities that often lack access to healthcare services even during the best of times.”
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more please visit: www.dtxalliance.org.
Arlington, VA: In June, the Digital Therapeutics Alliance (DTA) lauded the vision of Representatives DeGette (D-CO) and Upton (R-MI) on their CURES 2.0 Initiative and their leadership “in eliminating barriers to innovation in the healthcare system.” DTA provided a letter with recommendations that align with our Alliance’s ongoing 2020 global initiative to break down patient access obstacles to clinically-evaluated digital healthcare.
Our comments highlighted how major healthcare payors in the United States, such as Express Scripts, CVS Health, Cigna, and individual BlueCross and BlueShield plans, offer digital therapeutic options to their commercial customers. However, since traditional Medicare and Medicaid plans do not currently have systems in place to recognize and offer access to digital therapeutics, aging and low-income populations are denied access to these remotely delivered, evidenced-based treatment options.
Digital therapeutics are critical to patient care, particularly in their ability to address the following issues:
“The impacts of Covid-19 on patients and clinicians continue to grow as quarantines are extended, as vulnerable populations are increasingly at risk of viral exposure, and healthcare resources are further restricted to those requiring acute care,” said Megan Coder, DTA Executive Director. “While digital therapeutics do not treat Covid-19, they directly impact critical consequences of this pandemic. Yet today, patients covered by publicly funded programs rarely have access to this category of medicine.”
Digital therapeutics deliver therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of behavioral, mental, and physical diseases and disorders. These products differ from health and wellness apps, telehealth platforms, or tools solely designed for monitoring, diagnostic, and adherence purposes. DTx products comply with rigorous patient-centered core principles and best practices to ensure product integrity, user-centered designs, patient privacy through HIPAA (in the US), and validated clinical outcomes via randomized controlled trials (RCT) and real world evidence (RWE).
“Product quality, patient access, and appropriate utilization are critical for all digital therapeutics,” emphasized Coder. “We support quality standards to ensure that patients and clinicians can be assured they are accessing a trustworthy treatment that has undergone rigorous clinical research. Building on the ease of product scalability and access through patient-owned devices, DTx products can more easily reach high-risk, rural, and underserved communities that often lack access to healthcare services even during the best of times.”
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more please visit: www.dtxalliance.org.
In early April 2020, the Digital Therapeutics Alliance (DTA) announced an ‘Urgent Access’ campaign to provide individuals covered by publicly funded programs with increased access to clinically evaluated digital therapeutics (DTx) from the safety of their homes. Digital therapeutics, while not intended to treat COVID-19, have the potential to offer tremendous relief to patients and caregivers, strengthen patient-clinician relationships, and provide actionable insights as we collectively rebuild our new normal during and following this pandemic.
The next phase of DTA’s ‘Urgent Access’ campaign expands the spotlight to DTx product quality and appropriate utilization. Our goal is to provide clarity on how patients, clinicians, and payors can identify, access, and appropriately use clinically evaluated digital therapeutics for the purpose of treating, managing, and preventing a broad spectrum of behavioral, mental, and physical diseases and disorders. Our Alliance is committed to increasing available resources for end users and decision makers on how to explore and adopt the potential benefits of DTx products throughout the pandemic and beyond, while minimizing the risk of potential harm from experimental products and not-yet proven therapies.
Product Claims Matter. Is this product a digital therapeutic?
Digital health products have been available to patients for well over a decade. During this time, the types of product claims, purposes, safety, and levels of clinical evidence have diversified significantly. It is therefore becoming increasingly difficult for end users to know how to properly evaluate digital health products prior to use.
General digital health products that capture, store, or transmit health data – such as lifestyle apps, fitness trackers, and consumer health information – do not necessarily require clinical evidence, real world outcomes, or regulatory oversight. In comparison, digital therapeutics – software products that treat, manage, or prevent diseases and disorders – must demonstrate clinical evidence, real world outcomes, patient privacy and security protections, and regulatory oversight as required to support product claims of risk, efficacy, and intended use.
Patients and clinicians must not only understand what a product claims to do, but also what clinical evidence is available, or even necessary, as they face the difficult decision of determining which products will best meet their needs. To assist in this navigation process, DTA members are mobilizing to provide end users and decision makers with the tools they need to make informed decisions.
Product Quality Matters. What can I expect from a digital therapeutic?
Quality extends from the components and processes used to manufacture DTx products, to the quality management systems relied on to ensure patient safety, all the way through to the outcomes achieved by these therapies. Based on industry standards, only those software products that meet the following ten criteria are considered a digital therapeutic:
To protect against the risk of counterfeit, unproven, or potentially harmful products, these criteria provide end users and decision makers with a strong framework to understand and evaluate digital therapeutic products.
Product Access is Necessary. How can payors provide access to DTx products?
To assist public and private payors in providing access to DTx products that meet the criteria outlined above, DTA provides the following considerations (please refer to this worksheet for further detail):
Payors should also consider product implementation and scalability, clinical appropriateness, patient engagement and sustainability, privacy and security requirements, and the value provided to patients, caregivers, and clinicians — including improved health outcomes, reduced overall healthcare utilization costs, and individual and population health benefits.
National coverage frameworks for digital health products, which include access to DTx products, are currently being implemented in Germany and Belgium, while France and the United Kingdom have been reimbursing the use of DTx products regionally for more than three years.
In the United States, DTx products most frequently receive third-party payment by employers, PBMs, or insurers. Unfortunately, digital therapeutics are not currently reimbursed by Medicare or most state Medicaid programs, although we urge the federal government to take action in line with DTA’s ‘Urgent Access’ campaign.
Appropriate Utilization is Crucial. How can clinicians ensure that DTx products are used appropriately?
DTx products provide evidence-based therapy options for a wide variety of physical, mental, and behavioral conditions. Of primary concern to clinicians is clearly understanding which disease or condition the product has been indicated to treat, manage, or prevent. DTx products may be used independently, in tandem with remote or in-person clinician-delivered therapy, and/or paired with medications, devices (e.g., sensors, glucometers), and other therapies to optimize patient outcomes.
For products requiring clinician authorization, the following “DTx Rights” will help guide appropriate product utilization and ensure that the right care is delivered at the right time (please refer to this worksheet for further detail). Is this DTx product being used for the:
Digital therapeutics are designed to meet specific patient needs at specific times. They align with clinical guidelines, integrate into health systems, and are used in the context of patients’ current care plans. It is therefore crucial that appropriate product utilization is ensured once access to high quality digital therapeutics has been provided.
Moving Forward
Digital therapeutics create new treatment and self-management options for mental health and chronic disease populations. Building on the ease of product scalability and access through patient-owned devices, DTx products can more easily reach high-risk, rural, and underserved communities that often lack access to healthcare services even during the best of times.
In line with our mission, and in direct response to the quickly evolving global landscape, DTA will continue to develop resources for patients, caregivers, clinicians, payors, and government agencies to ensure the optimal utilization of, and access to, high quality DTx products.
Learn More
About
Founded in 2017, the Digital Therapeutics Alliance (DTA) is a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics (DTx). DTA has over 35 global members, located in 15 countries across four continents.
Whether DTx products are used independently or by clinicians in the course of in-person, remote, or digital care models, DTA stands behind rigorous patient-centered core principles, ethical standards, and product development best practices to ensure product integrity, user-centered designs, patient privacy, and validated clinical outcomes.
DTA does not function as a certification, accreditation, or standard setting body. Nor does DTA endorse specific DTx products.
STAT (Erin Brodwin & Rebecca Robbins) — A prominent trade group is calling on the federal government to cover digital health tools for people with public health insurance during the coronavirus pandemic, which has forced widespread delays in routine care.
These tools, known as digital therapeutics, use software and smartphone apps to connect patients with tips and coaching for diseases like diabetes. For the most part, they are not currently covered for Medicare or Medicaid patients, though some private Medicare Advantage plans and Medicaid managed care organizations have contracted with digital diabetes prevention and care providers. Employers and commercial insurance plans, however, are increasingly paying to make the tools available for their workers and members.
“Urgent Access” campaign aims to provide individuals covered by publicly funded programs with increased access to clinically evaluated digital therapeutics from the safety of their homes during this critical time.
ARLINGTON, VA – April 7, 2020 – During this uniquely challenging time, patients with chronic diseases and mental health conditions are struggling to receive consistent medical care due to travel restrictions and isolation measures resulting from the COVID-19 crisis.
In response, the Digital Therapeutics Alliance (DTA) is announcing an industry-wide “Urgent Access” initiative to further expand patient access to clinically evaluated digital therapeutics (DTx). DTx products deliver therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a spectrum of medical conditions. DTA’s legislative and regulatory proposals intend to provide new therapeutic options for patients with critical unmet needs during this pandemic.
“The impacts of COVID-19 on patients and clinicians continue to grow as quarantines are extended, as vulnerable populations are increasingly at risk of viral exposure, and healthcare resources are further restricted to those requiring hospital care,” said Dr. Megan Coder, DTA executive director. “While digital therapeutics do not treat COVID-19, they directly impact critical consequences of this pandemic. Yet today, patients covered by publicly funded programs rarely have access to this category of medicine.”
Campaign to Provide Patient Access
DTA’s urgent, multi-pronged effort for immediate legislative and regulatory changes will benefit patients through increased access to clinically evaluated DTx products during this critical time:
Additionally, DTA is highlighting the efforts member companies are undertaking to directly engage in the pandemic response. DTA members are not only making DTx products available to patients in need, but companies are also donating medical supplies, manufacturing respirators, and producing medications that directly aid patients affected by COVID-19.
Risk of Overlooking Critical Benefits
Populations with chronic medical conditions such as diabetes, lung disease, and heart disease, in addition to those facing existing disparities and inequities in healthcare access, are at an increased risk of being hospitalized with COVID-19. When vulnerable populations do not have access from the safety of their homes to clinically-validated therapies that align with clinical guidelines and current care, they are at greater risk of worsening, relapsing, or requiring in-person care.
“The usual burdens faced by patients with chronic conditions are compounded during this challenging period,” shares Dr. Anand K. Iyer, Vice Chair, DTA Board of Directors. “The goal of digital therapeutics is to provide patients with safe and secure self-management and treatment mechanisms that align with their current care, while simultaneously improving health outcomes, reducing unnecessary costs, and significantly reducing emergency room visits and other in-person healthcare encounters.”
Specific to behavioral and mental health disorders, digital therapeutics address patient needs arising from standalone conditions, underlying mental health issues stemming from co-morbid chronic diseases, in addition to acute burdens resulting from COVID-19. As individuals under stay at home orders seek ways to treat and manage their conditions, the solitude of confinement may further add to their burden of disease.
“Even during the best of times, access to effective mental healthcare is a challenge for many. At a time like this, when many are isolated and suffering extraordinary stress, with healthcare systems being under enormous strain, this challenge is exacerbated. Digital therapeutics can play a critical role in rapidly meeting this need by providing safe and effective care that is deliverable remotely,” explains Peter Hames, Chair, DTA Board of Directors. “The ‘Urgent Access’ initiative mobilizes the whole digital therapeutics industry to provide help to millions in this time of need.”
A United Vision
Since DTA’s inception in 2017, we continue to unite the diverse digital therapeutics industry. What unites us, and differentiates us, is a commitment to representing the wide spectrum of digital therapeutics that have undergone rigorous clinical research to demonstrate the safety and efficacy of products’ ability to treat, manage, or prevent a broad spectrum of behavioral, mental, and physical diseases and disorders.
Whether DTx products are used by patients and clinicians to treat, manage, or prevent a disease; whether they are made available directly on a patient’s phone or are complemented by additional wearables and devices; and whether they are provided as a prescription or non-prescription product, there is tremendous value that digital therapeutics are able to offer to patients, caregivers, and clinicians during this critical period.
Looking ahead
Digital therapeutics offer solutions to country leaders as they search for new ways to: address the ever-increasing mental health burdens caused or exacerbated by COVID-19, enable patients with chronic diseases to have greater control of their conditions, and reduce unnecessary burdens placed on over-taxed clinicians and healthcare systems.
We are confident that digital therapeutics can bring tremendous personal and public health benefits to patients, caregivers, clinicians, and health systems. As an Alliance, we are committed to working alongside government and healthcare leaders who are looking to provide patients with access to this critical category of medicine.
Learn More
About
Founded in 2017, the Digital Therapeutics Alliance (DTA) is a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics (DTx). DTA has over 35 global members, located in 15 countries across four continents.
Whether DTx products are used independently or by clinicians in the course of in-person, remote, or digital care models, DTA stands behind rigorous patient-centered core principles, ethical standards, and product development best practices to ensure product integrity, user-centered designs, patient privacy, and validated clinical outcomes.
DTA does not function as a certification, accreditation, or standard setting body. Nor does DTA endorse specific DTx products.
During the COVID-19 crisis, members of the Digital Therapeutics Alliance (DTA) have answered the call to serve their communities. While each contribution differs, all reflect the unifying DTA mission “to enhance healthcare quality, outcomes, and value for patients, providers, and payors.”
DTA member companies are not only dedicated to ensuring the manufacture and support of high quality digital therapeutics. Many of our members are also engaged in the development of pharmaceuticals, medical devices, technology platforms, and general digital health products. We are proud to represent each of these companies as they serve their communities in a variety of ways.
In relation to the broader healthcare industry:
Fighting on the front lines: DTA member companies are contributing resources critical to the front lines of this fight. Health Catalyst developed a tool to aid healthcare systems in forecasting the hospital impact of COVID-19, while other members are stepping up production to meet these predicted needs. Philips and ResMed have both significantly increased their manufacturing of ventilators and other critical medical equipment. These companies are collaborating with global leaders to overcome capacity and logistical challenges, with their employees working long hours to meet these heightened production goals. Additionally, Bayer, Novo Nordisk, Sanofi, Orexo, and other members are donating critical medical supplies, money, and other resources to assist governments, health workers, and patients in need of assistance.
S3 Connected Health developed ACORRD (Assessment Of COVID-19 Risk of Respiratory Deterioration), a web-based clinical support tool designed to help hospitals optimise and scale acute respiratory care amid the rising number of coronavirus cases. This will help specialists identify patients most in need of their attention, while providing decision-making support for clinicians less experienced in respiratory care so health workers can be drafted in from other departments to help bolster respiratory teams.
Developing potential treatments: DTA member companies are actively engaged in research to develop potential treatments and vaccines for COVID-19. Sanofi is undertaking the development of vaccine candidates, as well as research for potential treatment options. Bayer is undertaking a search for new active substances that may treat COVID-19, while Boehringer Ingelheim is screening their molecule library to identify potential candidates that could fight the virus. Similarly, Novartis is contributing to global research efforts, supporting communities, and ensuring a stable supply of essential medicines.
Informational research: Members are also compiling useful resources on their websites related to COVID-19. The Association of Diabetes Care and Education Specialists provides targeted resources for diabetes care and education specialists since these individuals are on the front line of care for patients affected by diabetes, prediabetes, and other cardiometabolic conditions. Additionally, Propeller Health, DarioHealth, Welldoc, Better Therapeutics, Kaiku Health, and Global Kinetics Corporation provide educational content and resources for patients, caregivers, and clinicians amid the COVID-19 outbreak.
Specific to mental health-focused products:
The core contribution of our members remains their ability to deliver high quality, clinically validated digital therapeutics that enable patients to treat or manage their health conditions in the safety of their home during this precarious time. With large percentages of the global population under “stay at home” orders, many individuals are experiencing heightened mental health and behavioral concerns. Additionally, doctors, nurses, pharmacists, and fellow frontline workers are under tremendous strain during this time. DTA members are therefore stepping up to offer services to these quarantined populations and frontline workers.
Big Health, a digital therapeutics company, has extended no-cost community access to their mental health solutions: Sleepio for poor sleep, and Daylight for worry and anxiety. In response to COVID-19, their team created quick-access versions of their solutions and in the first two weeks, over 70 employers across the US and the UK have made the mental health solutions available. A few of the companies include Nike, H-E-B, Compass Group, AdventHealth, TTEC, Target, BJC Healthcare, UCSF, the UK Department of Health & Social Care, and the NHS staff of England, which covers 1.2 million individuals.
SilverCloud Health’s digital therapeutic is being provided by Express Scripts to members during the COVID-19 pandemic to clients and their members at no cost. This product is based on principles of cognitive behavioral therapy (CBT), mindfulness, and positive psychology. These action-oriented products help members build self-awareness and self-management skills to improve emotional health.
In addition, Shoppers Drug Mart is making peace of mind a little more accessible to Canadians as they struggle with increased stress in the face of COVID-19. In partnership with SilverCloud Health, the company has opened a virtual stress management program, accessible anywhere from their phones, tablets, or computer. The company will cover all associated costs.
Hello Sunday Morning’s Daybreak program has achieved expanded reimbursement from the Australian Government. This will support an additional 10,000 people in managing alcohol-use-disorder, during the COVID-19 pandemic. As a digital program that combines a supportive online community with access to trained health coaches, Daybreak provides a unique alternative to face-to-face support during this time.
And featuring the wellness products from member companies, Happify is providing specially curated content including webinars and live weekly yoga, while Headspace has a free “Weathering the Storm” program of meditations, sleep, and movement exercises.
Looking forward:
Before, during, and after this pandemic, one thing remains the same: DTA members are committed to the delivery of innovative regimens to enhance patient healthcare outcomes. We will continue to update this list to feature steps our members are taking to be a part of the global fight against COVID-19.
Version: 6 April 2020
As COVID-19 continues to impact how populations with chronic diseases and mental health conditions across the world are living and receiving healthcare, it is important to consider how the use of a new category of medicine may address some of the emerging challenges – and increasingly growing pressures – introduced by the new realities of life created by COVID-19.
First, what is a digital therapeutic?
Digital therapeutics (DTx) deliver therapeutic interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of behavioral, mental, and physical diseases and disorders. These products are not intended to directly treat COVID-19.
DTx products may be used independently or in tandem with remote or in-person clinician-delivered therapy to optimize patient outcomes. They differ from lifestyle and wellness apps, adherence, diagnostic, and telehealth products.
Digital therapeutics undergo clinical trials, collect real world outcomes, and are based on patient-centered core principles and product development best practices, including product design, usability, data security, and privacy standards.
How could DTx products address prevailing concerns resulting from COVID-19?
Patients with chronic diseases are facing new challenges in the midst of the COVID-19 pandemic. These individuals still need to manage their conditions, but no longer have as much flexibility in seeing their healthcare providers, picking up and managing their medications, exercising, and eating well-balanced meals, among many other things. The current burden of COVID-19 exacerbates how patients are able to self manage their conditions due to physical distancing, isolation, and complications in accessing healthcare services.
What value could DTx products bring to this situation?
Patients with anxiety, depression, cognitive impairments, and other mental health conditions are also facing new challenges in the midst of the COVID-19 pandemic. With an increased focus on social distancing, people are facing long periods of quarantine, social isolation, and uncertainty. These conditions are often significantly impacted by stress, and children and adults will likely not receive the stimulation they normally would for long periods of time. Healthcare systems do not currently have the capacity to provide evidence-based therapies to all of the individuals dealing with mental health conditions and disorders. This represents a high degree of unmet medical need.
What value could DTx products bring to this situation?
Healthcare systems are searching for ways to reduce unnecessary clinic visits and hospitalizations for non-acute conditions. If the environmental conditions necessitated by COVID-19 push patients with mental health and chronic disorders into uncontrolled states, these individuals are more likely to require immediate care, thus delivering an additional strain on the healthcare system. Additionally, for patients over the age of 70, this presents an increased likelihood of them being exposed to the virus, infecting others, or demonstrating worse clinical outcomes.
What value could DTx products bring to this situation?
Patient Access
In order to address growing mental health needs, provide remote care for patients with chronic conditions, limit viral exposure for aging populations, and reduce unnecessary burdens on clinicians and health systems, it is crucial for patients to be given access to evidence-based digital therapies from the safety of their home environment.
National coverage frameworks for digital health that include DTx products are currently being implemented in Germany and Belgium, while France and the United Kingdom have been financing DTx products regionally for more than three years.
In the United States, DTx products most frequently receive third-party payment by employers, PBMs, or insurers. Unfortunately, digital therapeutics currently are not reimbursed by Medicare or most state Medicaid programs.
Conclusion
This is a challenging and disruptive time for everyone. As we all take the steps necessary to keep our loved ones and ourselves healthy, safe, and cared for, it is important to consider technologies that are available to provide accessible treatments wherever a patient is located, without creating an additional burden on medical professionals.
Patient access to and utilization of digital therapeutics could improve health outcomes, thereby reducing chronic disease-related hospitalizations, mitigating additional pressures on healthcare providers during the COVID-19 outbreak, and reducing vulnerable populations’ potential coronavirus exposure.
About DTA
Founded in 2017, the Digital Therapeutics Alliance (DTA) is a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. DTA has over 35 global members, located in 15 countries across four continents.
DTA does not function as a certification, accreditation, or standard setting body. DTA does not endorse specific digital therapeutic (DTx) products, nor does information provided through DTA intend to serve as patient-specific medical advice.
Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that renowned pediatrician and 2018 Past President of the American Academy of Pediatrics (AAP), Dr. Colleen Kraft, has joined the company as Senior Medical Director of Clinical Adoption. Dr Kraft’s expertise and experience will be used to assist in the broad adoption of Cognoa’s digital therapeutics by pediatricians to fundamentally enhance the standard of care for children with behavioral conditions, starting with autism.
Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation at the Endocrine 2020 conference. The presentation will include data from a pilot study of Better’s software-only prescription digital therapeutic in patients with type 2 diabetes. The conference will take place on March 28-31, at San Francisco’s Moscone Center.
The pilot studied 74 participants with type 2 diabetes and a baseline HbA1c ≥ 7%. Diabetes is defined by an HbA1c value of 6.5% or higher. In addition, study participants had a mean age of 55.2 years, baseline BMI of 34.7 kg/m2, 10.6 years since diagnosis of type 2 diabetes and 72% were female.
Voluntis (Euronext Paris, Ticker: VTX), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients. Leveraging Theraxium Oncology, Voluntis’ core platform for digital therapeutics in oncology, the collaboration will evaluate potential solutions that will support management of patient symptoms and remote monitoring by healthcare providers.